A rapidly advancing area of cancer treatment, “nanomedicine” uses materials at the nanoscale to target cancer cells precisely while limiting harm to healthy tissues and lowering systemic toxicity. Localized cancer therapies leverage nanotechnology by utilizing carriers such as nanoparticles, liposomes, and dendrimers, to enhance drug solubility, bioavailability, and targeted delivery to the tumor site. The enhanced permeability and retention (EPR) effect facilitates the retention of these nanomedicines at cancer sites, while surface modifications and specific targeting ligands increase therapeutic efficacy and personalization. Theranostic agents enable simultaneous therapy and diagnosis, offering real-time monitoring and optimized treatment. Despite the promising potential, challenges such as regulatory approvals, production scalability, and tumor microenvironment (TME) complexity hinder clinical translation. Regulatory frameworks in regions like the United States, Europe, and Japan are evolving to address these issues. Continuous research and technological advancements are essential for overcoming the current limitations and achieving clinical success in cancer nanomedicine.